Although pertuzumab and/or T-DM1 are commonly prescribed as front-line treatments for HER2-positive BC patients globally, in China, pertuzumab and T-DM1 was only newly approved, thereby limiting their usage in Chinese patients. The gene discussed is ERBB2; the disease is breast cancer.